Mallinckrodt
Irish domiciled pharmaceutical / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Mallinckrodt Pharmaceuticals?
Summarize this article for a 10 year old
Mallinckrodt Pharmaceuticals is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents.[2] In 2017, it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S.[3] Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid's most expensive drug.[4]
Company type | public liability company |
---|---|
OTC Pink: MNKTQ NYSE: MNK | |
ISIN | IE00BBGT3753 |
Industry | Pharmaceutical |
Predecessor | Mallinckrodt Inc. (before the 2013 tax inversion to Ireland) |
Founded | 1867; 157 years ago (1867) |
Headquarters |
|
Key people | Sigurdur (Siggi) Olafsson (CEO), Bryan Reasons (CFO) |
Revenue | US$3.162 billion (2019)[1] |
US$1.421 billion (2019)[1] | |
−US$1.822 billion (2019)[1] | |
Total assets | US$10.338 billion (2019)[1] |
Total equity | US$8.398 billion (2019)[1] |
Number of employees | 3,400[1] (2019) |
Website | mallinckrodt |
Mallinckrodt acquires (for repricing), manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals.[5] The company employed 5,500 and had net sales of $3.2 billion in 2017, of which $2.9 billion was from the U.S. healthcare system.[5]
The company has been implicated as a major contributor to the prescription opioid scandal around the over-prescription of oxycodone in the United States.[6]